Boston Scientific Corp

BSX remains in a Stage 4 – Decline under persistent lower highs and lower lows with down-sloping EMAs. The medium-term bias is Bearish, reinforced by the Support Failure primary pattern and continuation price structure. In the short term, price has been rejected at the 9/21EMA cluster near prior support turned resistance, indicating a timely sell opportunity. Long-term structural bias remains Bullish given the extended uptrend over the 3-year window.

• ↑Q1 2026 revenue $5.203B (+11.6% YoY) and EPS $0.80 (+6% YoY) beat consensus
• ↑Proposed Penumbra acquisition closing in 2026 strengthens interventional oncology
• ↓Full-year organic growth guidance trimmed from 10–12% to 6.5–8% for 2026